



FOR IMMEDIATE RELEASE

Contact: Murray Penner

(202) 434-8090

mpenner@NASTAD.org

**ADAP Crisis Task Force Reaches Agreement with
Boehringer Ingelheim to Assist Struggling ADAPs;
*Continues Call for Increased Federal and State Funding***

July 8, 2010, Washington, DC – As part of ongoing efforts by the ADAP Crisis Task Force (ACTF) and the pharmaceutical industry to address the unprecedented need for access to antiretroviral medicines through AIDS Drug Assistance Programs (ADAP), the ACTF announced today that it has reached an agreement with Boehringer Ingelheim. Additional discounts and rebates on HIV medicines produced by Boehringer Ingelheim will be provided to the country's ADAPs, beyond existing ones mandated by health reform and included in previous agreements with the ACTF. Boehringer Ingelheim also will freeze its prices for ADAPs through 2012.

"We appreciate Boehringer Ingelheim's willingness to come to the table and be a part of the collective solution to this crisis" stated Jennifer Brown, Director of the Bureau of Epidemiology at the Utah Department of Health and spokesperson for the ACTF. "We also understand that industry alone cannot close the entire gap. Additional state and federal funding is required to avoid a growing public health crisis," added Brown.

The agreement with Boehringer Ingelheim comes at a time when the combination of the nation's current economic situation, increased HIV testing efforts and state budget cuts has resulted in an unprecedented acceleration in the number of ADAP enrollees, resulting in severe cost containment measures in many ADAPs. As of July 1, there were 2,090 individuals in 11 states on waiting lists for ADAP. In addition to the current waiting lists, 12 states have implemented or will implement additional access restrictions such as lowering financial eligibility criteria, removing drugs from their formularies and limiting expenditures. To view a list of current ADAP access restrictions, please visit www.NASTAD.org.

The ACTF previously reached agreements with Abbott Laboratories, Gilead Sciences, Merck, Inc., Tibotec Therapeutics and ViiV Healthcare. Negotiations continue with Bristol-Myers Squibb and Genentech. "We are

confident that agreements with the remaining manufacturers, similar to this one with Boehringer Ingelheim and those already in place with other companies, can be accomplished soon," remarked Dwayne Haught, Manager of the HIV Medication Program for the Texas Department of State Health Services and a member of the ACTF. "These agreements are a critical component of our nation's collective response to help meet the medication needs of nearly 200,000 HIV-positive Americans," added Haught.

The National Alliance of State and Territorial AIDS Directors (NASTAD) routinely monitors the status of ADAP programs. While the program will yield savings from these agreements with pharmaceutical partners, the ongoing state budget crises coupled with the increased numbers of clients seeking ADAP services continues to require a significant increase in funding.

In addition to price freezes and increased discounts and rebates from companies and the recently announced \$25 million in reprogrammed funding from the federal government to address this crisis, additional funds from the federal and state governments are all necessary to sustain ADAPs until health reform is fully implemented in 2014. NASTAD estimates the program is in need of an additional \$126 million in FY2010 emergency federal funding an additional \$370 million in FY2011 federal funding, as well as ongoing and increased funding from state governments.

The ADAP Crisis Task Force (ACTF) was formed in December 2002 by a group of state AIDS/ADAP directors concerned about the nationwide fiscal crisis facing ADAPs. The ACTF works with pharmaceutical manufacturers of antiretroviral medications to reduce drug costs and improve access to medications for clients in the nation's ADAPs. NASTAD provides logistical support for the ACTF.

Founded in 1992, NASTAD is a nonprofit national association of state and territorial health department HIV/AIDS program directors who have programmatic responsibility for administering HIV/AIDS and viral hepatitis health care, prevention, education, and supportive services programs funded by state and federal governments. For more information, visit www.NASTAD.org.

###